Medical Treatment of Obesity

Richard Lindquist M.D.
Seattle, WA
Disclosures

- Novo Nordisk advisory council
- Retrofit advisory board
The Obesity Medicine Association’s Definition of Obesity

“Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in adverse metabolic, biomechanical, and psychosocial health consequences.”
Multiple treatment algorithms exist, with largely convergent content

- Obesity Medicine Association (OMA)
- American Heart Association/The American College of Cardiology/The Obesity Society (AHA/ACC/TOS)
- American Association of Clinical Endocrinologists (AACE/ACE)
- American Diabetes Association (ADA)

- All are open source
- Differences are largely in degree of detail
- Some variation wrt medication options
- Some variation in staging tools
- User friendliness, or lack of
**Current Treatment Options for Obesity**

*Potency includes many factors, such as the amount, rate, and sustainability of weight loss, and the long-term resolution of adiposopathy and fat mass disease. Potency varies greatly for each individual (i.e., long-term adherence to a lifestyle program can be as potent as gastric bypass surgery).*
Treatment Guidelines

Overweight/Obesity Treatment Algorithm

Step 1: Evaluation for Complications and Staging

- Cardiometabolic Disease
  - No Complications
    - BMI 25–26.9, or BMI ≥ 27
  - BMI ≥ 27 with Complications
    - Stage Severity of Complications
      - Low
      - Medium
      - High

Step 2: Select

- Lifestyle Modification:
  - MD/RD counseling; web/remote program; structured multidisciplinary program

- Medical Therapy:
  - phentermine; orlistat; lorcaserin; phentermine/topiramate ER; naltrexone/bupropion; liraglutide

- Surgical Therapy (BMI ≥ 35):
  - Lap band; gastric sleeve; gastric bypass

Step 3

If therapeutic targets for improvements in complications not met, intensify lifestyle and/or medical and/or surgical treatment modalities for greater weight loss.

Edmonton Obesity Staging System (EOSS)

Stage 0
- Absent
- Absent
- Absent

Stage 1
- Pre-clinical risk factors
- Mild

Stage 2
- Co-morbidity
- Moderate

Stage 3
- End-organ damage
- Severe

Stage 4
- End-stage
- End-stage

Obesity

Sharma AM & Kushner RF, *Int J*
Obesity as a Chronic Disease

- Long term problem, not likely to improve without treatment
- Treatable and manageable, not thought of as “curable”
- Stopping treatment leads to recurrence or relapse
- Strategies are Long Term!
- Multidisciplinary care continuum approach
Chronic Disease Examples

Hypothyroidism
Symptoms

High blood pressure

Obesity

Diabetes
Metabolic Syndrome

- AKA Dysmetabolic Syndrome
- AKA Syndrome X
- AKA “Insulin Resistance”
- ICD 10 code E88.9
- “Syndrome” of combination abnormalities:
  - Blood pressure
  - Lipids
  - Glucose
  - Increased abdominal girth
  - +/- microalbuminuria
- Metabolic Syndrome leads to Cardiometabolic Risk
**Inflammatory Cytokines**
- TNF-α
- Interleukin-1
- IL-6
- IL-8
- Resistin
- Monocyte Chemotactic Protein (MCP)
- Adipsin
- Plasminogen Activator Inhibitor-1 (PAI-1)
- Angiotensinogen
Cytokines and Inflammation

- Inflammatory Cytokines
  - TNF-α
  - Interleukin-1
  - IL-6
  - IL-8
  - Resistin
  - Monocyte Chemotactic Protein (MCP)
  - Adipsin
  - Plasminogen Activator Inhibitor-1 (PAI-1)
  - Angiotensinogen

- “Downstream” Effects
  - Inflammation
    - CRP
  - Thrombosis
  - Atherosclerosis
  - Dyslipidemia
  - Type 2 Diabetes
  - Hypertension
  - Metabolic Syndrome
  - Cardio-Metabolic Dz
  - Androgen Deficiency
Insulin Resistance is Central to Multiple Pathologic Conditions

- Hypertension
- Obesity
- Dyslipidemia
- Impaired Glucose Tolerance
- Diabetes 2
- Acanthosis Nigricans
- Atherosclerosis
- Decreased Fibrinolytic Activity (Thrombosis)
- Hyperuricemia
- Polycystic Ovary Disease
- Decreased Fibrinolytic Activity (Thrombosis)
- Insulin Resistance
- Polycystic Ovary Disease
- Dyslipidemia
- Impaired Glucose Tolerance
- Diabetes 2
- Acanthosis Nigricans
- Atherosclerosis
- Decreased Fibrinolytic Activity (Thrombosis)
- Hyperuricemia
- Polycystic Ovary Disease
- Obesity
Factors Contributing to Cardiometabolic Risk

- Metabolic Syndrome
  - Lipids, BP, Glucose

- Obesity

- Cardiometabolic Risk
  - Diabetes/CVD Risk

- Abnormal Lipids

- Hypertension

- Smoking, Physical Inactivity

- Age, Race, Gender, Family History

Source: Brunzell, et al. JACC 2008; 51:1512-1524
Natural History of Type 2 Diabetes

Years from Diagnosis

-15 -10 -5 0 +5 +10 +15

Insulin Resistance and Beta cell dropout begin years before Impaired Glucose Tolerance or other clinical signs.

Diagnosed Diabetes

Cardiovascular Complications

Impaired Glucose Tolerance

Insulin Resistance

Obesity Treatment Strategies

Diet

Surgery

Behavior and Lifestyle Modification

Medication Management

Exercise
Diet – Caloric Composition

• 0-400
  • Starvation or near starvation, never recommended

• 400-800
  • Very Low Calorie Diet (VLCD)

• 800-1500
  • Low Calorie Diet (LCD)

• Above 1500
  • Balanced Deficit Diet (BDD)
    – Reduction of 500-1000 cal/day from DMR
Diet – Nutritional Composition

Macronutrients

- Low Fat
  - AHA, Ornish, Pritikin

- Low Carb
  - Atkins

- High Fat
  - Atkins

- High Protein

Names associated with diets are examples only
Diet – Type or Brand

- Atkins
- Protein Power
- ZONE
- LEARN (balanced deficit)
- ADA (diabetic)
- South Beach
- Weight Watchers
- Jenny Craig
- Nutrisystems
- Optifast
- HCG

- Mediterranean
- Body for Life
- DASH
- AHA
- Pritikin
- Ornish
- “Whole Food, Plant Based”
- Vegan
- Vegetarian
- Kosher
- Halal
Diet – Is there a “Best” diet?

• Diet should be individualized

• All diets can be described in terms of caloric content and macronutrient content

• Many different diets have strong adherents

• All diets can be effective in weight loss

• Most obesity medicine specialists use some version of a reduced carbohydrate approach
  – All calories are not created equal
Glucose and Insulin Response to a 300 Kcal Meal after 10 d of a high- (triangles), intermediate- (open circles), and low-carbohydrate (closed circles) diet (n=6).

Glucose AUC was lowest for the low-carbohydrate diet (p=0.001). Insulin AUC was different for each diet (p=0.001).

Carbohydrate Metabolism

- Carbohydrates
  - Glucose
  - Insulin
    - Fat Storage
    - Inhibition of Fat Burning
Diet

Behavior and Lifestyle Modification

Surgery

Medication Management

Exercise
Behavior and Lifestyle Modification

• Goal is to help patient learn behaviors and patterns of thinking that support weight loss and weight maintenance

• Varied counseling approaches are useful
  – Motivational Interviewing
  – Cognitive Behavioral Therapy
  – Relational/Interpersonal Therapy

• 5 A’s approach currently used by Centers for Medicare and Medicaid Services (CMS)
Five Major Steps to Intervention – The 5 A’s

- Ask
- Assess
- Advise
- Agree
- Assist
## Overall Approach

### Five A’s of Obesity Management

<table>
<thead>
<tr>
<th>Ask</th>
<th>Assess</th>
<th>Advise</th>
<th>Agree</th>
<th>Arrange/Assist</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Ask for permission to discuss body weight</td>
<td>• Assess body mass index, waist circumference, and obesity stage</td>
<td>• Advise the patient about the health risks of obesity, the benefits of modest weight loss, the need for a long-term strategy, and treatment options</td>
<td>• Agree on realistic weight-loss expectations, targets, behavioral changes, and specific details of the treatment plan</td>
<td>• Assist in identifying and addressing barriers</td>
</tr>
<tr>
<td>• Explore readiness for change</td>
<td>• Explore drivers and complications of excess weight</td>
<td></td>
<td></td>
<td>• Provide resources</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Assist in finding and consulting with appropriate providers</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Arrange regular follow-ups</td>
</tr>
</tbody>
</table>
Diet

Behavior and Lifestyle Modification

Surgery

Medication Management

Exercise
Exercise and Activity

• Part of a comprehensive plan
• More important for weight maintenance than weight loss
• Many benefits other than weight control
• Exercise Prescription
Exercise and Activity – How much does it contribute to weight loss?

- Not as much as we might think
- Example:
  - 45 yo female patient with DMR of 2200 cals per day.
  - 1100 Low Calorie Diet => diet deficit of ~1100 cal/day
  - Calories burned with 1 hour of walking ~300
Exercise and Activity

Many benefits other than weight control

• Mood
• Cardiovascular fitness
• Pain
• **Glucose control**
• Dyslipidemia
• Strength

• Balance/Coordination
• ADLs (Activities of Daily Living)
• Lowers risk of some cancers

http://www.cdc.gov/physicalactivity/everyone/health/
Medications

• Medications used to treat weight

• Medications that affect weight
Medications Used to Treat Weight

• Sympathomimetics
  • Phentermine
  • Phendimetrazine
  • Diethylpropion
• Metformin
  – Off label
• Topiramate
  – Off label
• Gastric Lipase Inhibitor
  • Orlistat (Alli® – OTC, Xenical® –RX)

• “New” Drugs
  • GLP-1 analogues
    • Liraglutide (Saxenda®)
• Combination
  • Phentermine/Topiramate (Qsymia®)
    • Bupropion/Naltrexone (Contrave®)
• Serotonergic (5HT-2cR)
  • Lorcaserin (Belviq®)
Medications Used to Treat Weight
Relative Advantages

- Sympathomimetics
  - Years of experience
  - Predictable
  - Inexpensive

- Newer Agents
  - Approved for extended use
  - Offer variety
  - Different mechanisms
Medications That Affect Weight

**Weight Positive (Gain)**
- Corticosteroids
- Antihistamines
  - Cyproheptadine (Periactin®)
- Many Antidepressants
  - MAOIs, TCAs, most SSRIs (esp paroxetine)
- Opioids
- Atypical Antipsychotics
  - risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone
- Most Antiseizure meds
  - (not topiramate or zonisamide)
- Many Diabetes meds
- Beta Blockers

**Weight Neutral**
- Venlafaxine (Effexor®)
- Citalopram (Celexa®)
- Sertraline (Zoloft®)

**Weight Negative (Lose)**
- Metformin
- Nefazodone (Serzone®)
- Bupropion (Wellbutrin®)
- Fluoxetine (Prozac®)
- Incretins
  - Exenatide (Byetta®, Bydureon®)
  - Liraglutide (Victoza®, Saxenda®)
# Diabetic Medications Effects on Weight

## Weight Positive (gain)
- **Insulins**
- **Thiazolidinediones (TZDs)**
  - rosiglitazone (Avandia®)
  - pioglitazone (Actos®)
- **Sulfonylureas**
  - glimepiride (Amaryl®)
  - glipizide (Glucotrol®)
  - glyburide (DiaBeta®, Glynase®, Micronase®)
- **Meglitinides**
  - nateglinide (Starlix®)
  - repaglinide (Prandin®)

## Weight Negative (lose)
- **Metformin**
- **GLP-1 analogues**
  - liraglutide (Victoza®, Saxenda®)
  - exenatide (Byetta®, Bydureon®)
- **DPP-4 Inhibitors**
  - sitagliptin (Januvia®)
- **Gliflozins**
  - SGLT-2 Inhibitors(sodium-glucose cotransporter 2)
    - canagliflozin (Invokana®)
    - dapagliflozin (Farxiga®)
    - empagliflozin (Jardiance®)
Surgery

Diet

Behavior and Lifestyle Modification

Exercise

Medication Management
“The new guidelines recognize for the first time surgery as a legitimate diabetes treatment and should inform physicians and policymakers about the appropriate selection of patients for surgical treatment. Both practically and conceptually it is one of the greatest innovations in diabetes care in recent times.”

Diabetes Care 2016 Jun; 39(6)
Algorithm for the treatment of T2D, as recommended by DSS-II voting delegates.

Francesco Rubino et al. Dia Care 2016;39:861-877
Summary

• Obesity is a chronic condition amenable to long term strategies
• Insulin resistance is central to many downstream metabolic diseases of obesity
• Carbohydrate metabolism is central to obesity and associated morbidities
• The concept of a “care continuum” is very useful and allows for combined approaches
Thank You!

Rick Lindquist M.D.
richard@richardlindquistconsulting.com
Cell 206.465.6905
New Concepts in PCOS

Paula Amato, MD
Department of Obstetrics & Gynecology
October 21, 2016
Disclosures

• None
Learning Objectives

• To review the diagnostic criteria and differential diagnosis for PCOS
• To discuss the role of environmental and genetic factors in the pathogenesis of PCOS
• To review the risk of DM, CVD, and other metabolic consequences of PCOS
• To discuss the therapeutic options for the treatment of PCOS
Definition (Rotterdam 2003)

• Diagnosis requires at least two of the following:
  – Oligo- or anovulation (oligomenorrhea)
  – Hyperandrogenemia or hyperandrogenism (acne, hirsutism)
  – Polycystic ovaries on ultrasound
• and, exclusion of other causes
Differential Diagnosis

- Non-classical (Late Onset) CAH
- Cushing’s Syndrome
- Hyperprolactinemia
- Hypothyroidism
- Premature ovarian insufficiency (POI)
- Androgen-secreting tumor
Diagnostic Work-up

- FSH, TSH, PRL, 17OHP, P4
- (LH, T, DHEAS)
- Lipids
- OGGTT (FBS or HgA1C)
- (Pelvic US)
- AMH ≥ 5 ng/ml
Polycystic Ovaries - US Criteria

- ≥ 12 follicles measuring 2-9 mm in diameter or increased ovarian volume (>10 cm³)
Polycystic Ovaries
Pathogenesis

• Insulin resistance/hyperinsulinemia
• Dysregulation of ovarian steroidogenic enzymes
• Gonadotropin dysfunction - ↑ GnRH pulse frequency
Basic Pathophysiology of Hyperandrogenemia in the Polycystic Ovary Syndrome.

Insulin Resistance & PCOS

• Women w/ PCOS are insulin resistant compared with BMI-matched controls
• Also, defect in pancreatic β cell function
• INSR d/t post-binding defect in signal transduction; increased serine phosphorylation of INSR & IRS-1 (Dunaif et al., JCI 1995)
BMI Group with PCOS vs. % Prevalence

$p \leq 0.001$

Prevalence (%)

BMI Group

- Underweight: 8.2
- Normal: 9.8
- Overweight: 9.9
- Class I Obesity: 5.2
- Class II Obesity: 12.4
- Class III Obesity: 11.5

BMI Group:

- Underweight: < 18.9
- Normal: 19.0 - 24.9
- Overweight: 25.0 - 29.9
- Class I Obesity: 30.0 - 34.9
- Class II Obesity: 35.0 - 39.9
- Class III Obesity: > 40.0
Prevalence of Glucose Intolerance by BMI in PCOS

\[ p < 0.001 \text{ by chi square for trend} \]
Insulin Resistance & PCOS

• Hyperinsulinemia enhances LH-mediated androgen secretion
• Insulin $\rightarrow$ ↓ SHBG $\rightarrow$ ↑ free testosterone
Ovarian Enzyme Activities in Women with PCOS

- Studies using primary ovarian tissue and cultured theca and GCs show that steroidogenic enzyme activities are upregulated in theca cells in PCOS (StAR, P450\textsubscript{SCC}, 3\(\beta\)-HSD, P450C17)
- Granulosa cells underexpress aromatase and overexpress 5\(\alpha\)-reductase
- Premature expression of LHR & P450\textsubscript{SCC}
- Net result - \(\uparrow\) androgen/estrogen ratio
Gonadotropin Dysfunction in Women with PCOS

• \( \uparrow \) GnRH pulse freq - 1\(^\circ\) vs 2\(^\circ\) to low progesterone levels \( \rightarrow \uparrow \) LH pulse freq/amp \( \rightarrow \uparrow \) LH/FSH ratio
• LH pulse amplitude is inversely proportional to BMI
• Recent ovulation (high P4 levels) \( \rightarrow \downarrow \) LH levels
• Elevated LH levels are not required for increased ovarian androgen secretion
Role of Genetic Factors

- PCOS is a heterogeneous disorder
- Prevalence of 6-8% in reproductive age women
- Higher incidence in Hispanics
- Complex, multigenic disorder
- Evidence for linkage and association of a marker locus on chr 19 near INSR gene
Role of Environmental Factors

- Association btw premature pubarche (PP) & hyperinsulinemia/hyperandrogenism (Ibanez et al, 90s)
- Association btw low birth weight (LBW) & PP
- Association btw LBW and PCOS
Role of Environmental Factors

• Prenatal growth retardation → endocrine-metabolic adaptations → hyperinsulinemia → postnatal wt catch-up → ovarian hyperandrogenism → premature pubarche → PCOS (fetal programming)

• Genetic modulators
Longterm Consequences of PCOS

- Obesity (30-75% of patients) - ↑ WHR; prevalence higher in US vs Europe
- ↑ risk of T2DM & gestational diabetes (GDM)
- HT & vascular dysfunction
- CVD
- Hyperlipidemia
- Obstructive sleep apnea
- Endometrial hyperplasia/cancer
- Depression and anxiety
Type II DM & PCOS

- Prevalence of glucose intolerance is 30-40% and of type II DM is 10% by 4th decade
- IR, βcell dysfunction, obesity, FHx of type II DM, personal hx of GDM → risk factors for DM
Metabolic Syndrome in Women with PCOS

- High prevalence of metabolic syndrome in PCOS across all age groups
- Metabolic syndrome is associated with an increased risk of CVD and type II DM
- Most prevalent metabolic components are ↓ HDL, obesity, and HT
- Free T and SHBG are major predictors of metabolic syndrome in PCOS
Evidence for the Association between PCOS and CVD

- Recognized CVR factors
  - ↑TC, ↑LDL, ↑TG, ↓HDL
- Emerging/novel CVR factors
  - ↑CRP; ↑WBC (lymphocytes & monocytes)
- Direct measurement of subclinical CVD
  - LVH & diastolic dysfunction, ↑IMT; endothelial dysfunction: FMD, ↑ET-1; impaired fibrinolysis (↑PAI-1)
- Increased clinical CVD
  - No increased mortality for CVD in PCOS
Fig. 1. Pathogenesis of cardiovascular disease in polycystic ovarian syndrome. Polycystic ovarian syndrome (PCOS) has been identified as a risk factor for cardiovascular disease. The multiple risk factors for cardiovascular disease that are associated with PCO...

Francesco Orio, Giovanna Muscogiuri, Cinar Nese, Stefano Palomba, Silvia Savastano, Domenico Tafuri, Giorgio Colarieti, Giovanbattista La Sala, Annamaria Colao, Bulent O. Yildiz

**Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome**


http://dx.doi.org/10.1016/j.ejogrb.2016.08.026
Treatment for Women with PCOS

• Infertility
  – CC, insulin-sensitizers, aromatase inhibitors, FSH, IVF

• Hirsutism
  – OCPs, antiandrogens

• Menstrual irregularity
  – OCPs or cyclic progestogens

• Weight/metabolic concerns
  – Diet/lifestyle modification, insulin-sensitizers, Orlistat, bariatric surgery
Treatment of Hirsutism/Acne

• OCPs
  – ↓ LH → ↓ androgen secretion
  – ↑ SHBG → ↓ free testosterone
  – Less androgenic progestins preferred
    (desogestrel, norgestimate, drosperinone)

• Antiandrogens

• Insulin-sensitizers
Treatment of Hirsutism/Acne

- Antiandrogens
  - Spironolactone 100-200 mg/d
  - Flutamide 250 mg/d; AR-blocker; concern re liver toxicity
  - Finasteride 5 mg/d; 5α-reductase inhibitor
Management of Oligomenorrhea

- Consider an endometrial biopsy to rule out endometrial hyperplasia
- OCPs
- Cyclic progestogens
- Levonorgestrel IUD
- Lifestyle modification/weight-loss
- Insulin-sensitizing medications
Management of the Adolescent and Young Women w/ PCOS

• Evidence that Metformin plus anti-androgen may normalize the metabolic abnormalities in PCOS

• Metformin-flutamide better than OCPs

• Metformin-flutamide + OCPs better than OCPs alone (Ibanez & de Zegher, Fertil Steril 2006)
Lifestyle Modification/Weight Loss

- Weight loss improves the reproductive and metabolic characteristic of overweight and obese patients with PCOS
- General recommendations:
  - Behavioral modification
  - Hypocaloric low GI diet
  - Moderate intensity aerobic exercise 30 min/d x 5d/wk
  - Orlistat can be considered
  - Metformin should be reserved for patients with T2DM
  - Consider bariatric surgery for obese PCOS patient with co-morbidities
<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pre Bariatric Events</th>
<th>Total</th>
<th>Post Bariatric Events</th>
<th>Total</th>
<th>Weight</th>
<th>Odds Ratio (Non-event) M-H, Random, 95% CI</th>
<th>Odds Ratio (Non-event) M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eid 2005</td>
<td>5</td>
<td>24</td>
<td>0</td>
<td>24</td>
<td>4.5%</td>
<td>0.07 [0.00, 1.39]</td>
<td></td>
</tr>
<tr>
<td>Dixon2002</td>
<td>2</td>
<td>107</td>
<td>0</td>
<td>107</td>
<td>4.2%</td>
<td>0.20 [0.01, 4.14]</td>
<td></td>
</tr>
<tr>
<td>Jama 2012</td>
<td>10</td>
<td>20</td>
<td>4</td>
<td>20</td>
<td>19.7%</td>
<td>0.25 [0.06, 1.02]</td>
<td></td>
</tr>
<tr>
<td>Talebpour2011</td>
<td>14</td>
<td>254</td>
<td>4</td>
<td>254</td>
<td>30.7%</td>
<td>0.27 [0.09, 0.85]</td>
<td></td>
</tr>
<tr>
<td>George2013</td>
<td>11</td>
<td>156</td>
<td>7</td>
<td>156</td>
<td>40.9%</td>
<td>0.62 [0.23, 1.64]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>561</strong></td>
<td><strong>561</strong></td>
<td><strong>100.0%</strong></td>
<td></td>
<td></td>
<td><strong>0.35 [0.19, 0.65]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Total events 42, 15

Heterogeneity: $\tau^2 = 0.00; \chi^2 = 2.99, df = 4 (P = 0.56); I^2 = 0%$

Test for overall effect: $Z = 3.31 (P = 0.0009)$
Management of Infertility in Women with PCOS

- Weight loss
- Optimize HgA1C and vitamin D levels pre-pregnancy
- Clomiphene citrate
- Aromatase inhibitors
- Insulin-sensitizing medications
  - Metformin
  - Thiazolinediones
- Gonadotropins
- IVF
Complications of Ovulation Induction

- Multiple pregnancy
- Ovarian hyperstimulation syndrome (OHSS)
Clomiphene Citrate (CC)

- Historically first-line drug of choice
- Antiestrogen
- Clomiphene citrate 50-150 mg D3-7
- 80% of patients with PCOS respond to CC
- Antiestrogen effects on endometrial lining and cervical mucus
- Clomiphene associated with a higher live birth rate than metformin and combination no better than clomiphene alone (Legro et al, NEJM ‘07)
Aromatase Inhibitors (Letrozole)

- Inhibit conversion of androgens to E2
- Letrozole 2.5-7.5 mg/d D3-7
- Letrozole associated with a higher live birth rate than clomiphene citrate (Legro et al, NEJM ‘14)
- Now considered first-line therapy in PCOS
- No antiestrogenic effects on end target tissues
- Well-tolerated
- Recent reports of teratogenicity - unsubstantiated
Metformin

- Biguanide; dose 500 mg tid or 850 bid
- Inhibits hepatic glucose production; increases glucose uptake in muscle
- Used in combination with CC, AI, or FSH in resistant patients
- ↓ ins, ↓ T, improve ovulation, ↑ preg rates
- Used to decrease risk of OHSS in PCOS patients during IVF
Thiazolinediones

• Results comparable to Metformin
• ? Safety in pregnancy
• Commonly cause edema & wt gain
Gonadotropins

• “Low-slow protocol” - monofollicular development
Ovarian Drilling (LOD)

- Resumption of ovulation and menstrual cyclicity in 80% of patients
- ↓ androgen levels, ↓ LH/FSH ratio, improved ovulation
- Controversial - risk of adhesion formation
- ↓ risk of multiple preg/OHSS
In-vitro Fertilization (IVF)

- Gonadotropins ± Meformin
- GnRH agonist (Lupron) trigger to decrease risk of OHSS
- \textit{In vitro} oocyte maturation (experimental)
Treatment Algorithm for Infertility in Patients with PCOS

Wt loss

↓

CC or Letrozole or Metformin

↓

(CC or Letrozole) + Met

↓

Low-slow Gonadotropins ± Met

↓

IVF
Role of Obesity in PCOS

- Obesity is likely not a cause of PCOS
- However, obesity does exacerbate many aspects of the phenotype
- Obesity is associated with a poor response to infertility treatment and likely an increased risk of pregnancy complications
- Encouraging weight loss is front-line therapy
- Further studies are needed to identify the best treatment
- The role of lifestyle therapies in women of normal weight with PCOS is uncertain
Obesity and Cancer

Bruce M. Wolfe, M.D., FACS, FASMBS

Portland, OR
Disclosures

EnteroMedics – consultant
BMI v. Mortality

Women

Calle: NEJM(1999);341:1097
BMI v. Mortality

Men

Calle: NEJM(1999);341:1097
All Cause Mortality vs. BMI

Flegal: JAMA(2013);309:71
Obesity: Cancer

Women

Calle: NEJM(2003);348:17
Obesity: Cancer

Men

![Graph showing the relative risk of death for various cancers in men associated with obesity.](image)

Calle: NEJM(2003);348:17
Unadjusted Cumulative Mortality

Sjostrom: NEJM 2007;357:741-52
## Cause of Death: SOS

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Surgery</th>
<th>HR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
<td>2037</td>
<td>2010</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular event</td>
<td>53</td>
<td>43</td>
<td>↓ 19%</td>
</tr>
<tr>
<td>Tumor</td>
<td>48</td>
<td>29</td>
<td>↓ 40%</td>
</tr>
<tr>
<td>Other</td>
<td>28</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>129</td>
<td>101</td>
<td>0.76</td>
</tr>
</tbody>
</table>

## Cause of Death: Utah

Number/10,000 person.yrs

<table>
<thead>
<tr>
<th>Cause</th>
<th>Control</th>
<th>Surgery</th>
<th>% Decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>18.5</td>
<td>9.7</td>
<td>48%</td>
</tr>
<tr>
<td>Cancer</td>
<td>13.3</td>
<td>5.5</td>
<td>60%</td>
</tr>
<tr>
<td>Other</td>
<td>25.3</td>
<td>22.4</td>
<td>11%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>57.1</strong></td>
<td><strong>37.6</strong></td>
<td><strong>34%</strong></td>
</tr>
</tbody>
</table>

Adams: NEJM (2007);357:753
Weight Loss Decreases Cancer Mortality
Possible Explanations

- Decreased cancer incidence
- Enhanced cancer survival
- Process of care
## Bariatric Surgery: Effect on Cancer Incidence

<table>
<thead>
<tr>
<th>Location</th>
<th>Control (n)</th>
<th>Surgery (n)</th>
<th>F/u, year</th>
<th>RR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quebec</td>
<td>5746</td>
<td>1035</td>
<td>5</td>
<td>0.22</td>
</tr>
<tr>
<td>Utah</td>
<td>9442</td>
<td>6596</td>
<td>12.5</td>
<td>0.76</td>
</tr>
<tr>
<td>Sweden</td>
<td>2037</td>
<td>2010</td>
<td>10.9</td>
<td>0.67</td>
</tr>
</tbody>
</table>

Fatal and Non-Fatal Cancer Incidence: SOS

**Men**
- Control
- Surgery
- HR 0.97 (95% CI 0.62-1.52)
- p=0.90
- n=39

**Women**
- Control
- Surgery
- HR 0.58 (95% CI 0.44-0.77)
- p=0.0001
- n=79

**Number at risk**
- Control: 590, 577, 457, 228, 49, 1447, 1410, 966, 498, 118
- Surgery: 590, 568, 458, 236, 62, 1420, 1390, 1108, 526, 129

Uterine Malignancy: Bariatric Surgery

Ward: Gyn Oncol 2014;144:63-65
## Incidence of Cancers by Stage

<table>
<thead>
<tr>
<th></th>
<th>Surgery (n)</th>
<th>Control (n)</th>
<th>HR</th>
</tr>
</thead>
<tbody>
<tr>
<td>In Situ</td>
<td>44</td>
<td>73</td>
<td>0.86</td>
</tr>
<tr>
<td>Local</td>
<td>128</td>
<td>219</td>
<td>0.86</td>
</tr>
<tr>
<td>Regional</td>
<td>49</td>
<td>98</td>
<td>0.61</td>
</tr>
<tr>
<td>Distant</td>
<td>28</td>
<td>68</td>
<td>0.61</td>
</tr>
</tbody>
</table>

Adams: Obesity 2009;17:796
Nutrition and Cancer

Diet

Overweight/Obesity

ACS Data: 20% cancer women
14% cancer men

Weight Loss: Bariatric Surgery
Cancer mortality reduced 60-80%
Obesity – Cancer

Plausible Mediators

• Insulin
• Estrogens
• Adipokines
• Inflammation
Insulin Related Compounds

Insulin: pancreatic islets

Insulin- like growth factor 1 (IGF-1): liver

Insulin-like growth factor binding protein (IGFBP-1)
Pre-Op & Post-Op Insulin, by Procedure
LABS-2

Insulin (pmol/L)

Time

Baseline 12 Months 24 Months 36 Months

RYGB

LAGB

163.5 161.1 101.4 93.8 106.6

47.9 49.3 52.8
Cancer and Diabetes

Diabetes associated with cancer of:

Liver, Pancreas, Endometrium, Colon/Rectum, Breast, Kidney

Glucose v. Insulin

T2DM: insulin $\uparrow$ cancer (OR 1.97)

Chang: J Clin Endocrinol Metab 2012;97:E1170
Obesity

Adipose tissue dysfunction

↑ Levels of ECM proteins and endotrophin

Adipocyte

↑ Aromatase activity

Hormones (estrogen)

Adipocyte progenitors

Lipid metabolites and lipolytic enzymes

Inflammatory cytokines (IL-6, TNF, CCL2, PAI-1)

Adipokines (leptin, adiponectin)

Obesity-induced systemic changes

Hyperinsulinaemia (insulin–IGF-1 signalling pathways)

Hyperglycaemia (hyperglycaemic memory)

Tumour initiation → Tumour progression → Drug resistance and cancer recurrence

Sex Hormones and Cancer

Androgens $\xrightarrow{\text{Cytochrome P450 aromatase}}$ Estrogens

Premenopause: ovaries
Postmenopause: adipose, skin

Obesity $\xrightarrow{\uparrow}$ Aromatase, $\uparrow$ Estrogens
Adiponectin

- Adipokine
- ↓ Obesity, ↑ with Weight Loss
- ↑ Insulin Sensitivity
- Cancer Inhibition
- ↑ Apoptosis
Breast Cancer Disease Free Interval
>20% Above Ideal BW, Adjuvant Chemotherapy

Bastarrachea: Ann Int Med 1994;120:18
Women’s Intervention Nutrition Study (WINS)

Early stage breast cancer survivors (n=2437) low fat diet, 5 years

<table>
<thead>
<tr>
<th>Weight loss</th>
<th>Control 0</th>
<th>Low fat ~3%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrence</td>
<td>Control HR 0.76</td>
<td>Low fat HR 0.58</td>
</tr>
<tr>
<td>Recurrence ER (-)</td>
<td>Control</td>
<td>Low fat</td>
</tr>
</tbody>
</table>

Pierce: JNCI 2006; 98:1767
Women’s Health Eating & Lifestyle (WHEL)

Early stage breast cancer survivors

↑ vegetable, fruit \( n = 3088 \)
f/u median 7.3 years, 518 relapse events

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Vegetable/Fruit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight Change</td>
<td>No difference</td>
<td></td>
</tr>
<tr>
<td>Recurrence</td>
<td>16.7%</td>
<td>16.9%</td>
</tr>
<tr>
<td>Survival</td>
<td>10.1%</td>
<td>10.3%</td>
</tr>
</tbody>
</table>

Chlebowski: J Natl Cancer Inst 2006; 98:167
Physical Activity Levels/BMI

Obesity – Cancer

Clinical Implications:

1) Current cancer screening

2) Consider bariatric surgery when fully recovered from primary cancer treatment
### Breast Cancer Screening

**American Cancer Society 2016**

<table>
<thead>
<tr>
<th>Age</th>
<th>Risk</th>
<th>Recommendation</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>40-44</td>
<td>Average</td>
<td>Mammogram Choice</td>
<td>1 yr</td>
</tr>
<tr>
<td>45-54</td>
<td>Average</td>
<td>Mammogram</td>
<td>1 yr</td>
</tr>
<tr>
<td>&gt;55</td>
<td>Average</td>
<td>Mammogram</td>
<td>2, 1 choice</td>
</tr>
<tr>
<td>&gt;30</td>
<td>(+) BCRA</td>
<td>Mammogram + MRI</td>
<td>1 yr</td>
</tr>
<tr>
<td>&gt;30</td>
<td>20-25% Lifetime</td>
<td>Mammogram</td>
<td>1 yr</td>
</tr>
</tbody>
</table>

# Cervical & Endometrial Cancer Screening

**American Cancer Society 2016**

## Cervical:

<table>
<thead>
<tr>
<th>Age</th>
<th>Risk</th>
<th>Recommendation</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>21-29</td>
<td>Average</td>
<td>PAP Test; HPV if needed</td>
<td>3 yr</td>
</tr>
<tr>
<td>30-65</td>
<td>Average</td>
<td>PAP + HPV</td>
<td>3 yr</td>
</tr>
<tr>
<td>&gt;65</td>
<td>NL in past</td>
<td>None</td>
<td>----</td>
</tr>
<tr>
<td>&gt;65</td>
<td>Past pre-cancer</td>
<td>Pap</td>
<td>3, 20 more years</td>
</tr>
</tbody>
</table>

## Endometrial:

<table>
<thead>
<tr>
<th>Age</th>
<th>Risk</th>
<th>Recommendation</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menopause</td>
<td>Average</td>
<td>Advise</td>
<td>----</td>
</tr>
<tr>
<td>35</td>
<td>High</td>
<td>Endometrial Bx</td>
<td>1 yr</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age</th>
<th>Risk</th>
<th>Recommendation</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;50</td>
<td>Average</td>
<td>Flexible Sigmoidoscopy</td>
<td>5 yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Colonoscopy</td>
<td>10 yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Barium Enema</td>
<td>5 yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CT Colonoscopy</td>
<td>5 yrs</td>
</tr>
</tbody>
</table>

1. ACS Colorectal Cancer Screening Tests (2016).

Prostate & Lung Cancer Screening
American Cancer Society 2016

Prostate:

<table>
<thead>
<tr>
<th>Age</th>
<th>Risk</th>
<th>Recommendation</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>Average</td>
<td>Discuss with Patient</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>African American, 1° relative</td>
<td>Discuss</td>
<td>Depends</td>
</tr>
</tbody>
</table>

Lung:

<table>
<thead>
<tr>
<th>Age</th>
<th>Risk</th>
<th>Recommendation</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>55-74</td>
<td>&gt;30 pk/yrs</td>
<td>LDCT</td>
<td>----</td>
</tr>
</tbody>
</table>

Pharmacotherapy in Obesity

Richard Lindquist M.D.
Seattle, WA
Disclosures

- Novo Nordisk advisory council
- Retrofit advisory board
Multiple treatment algorithms exist, with largely convergent content

- Obesity Medicine Association (OMA)
- American Heart Association/The American College of Cardiology/The Obesity Society (AHA/ACC/TOS)
- American Association of Clinical Endocrinologists (AACE/ACE)
- American Diabetes Association (ADA)

- All are open source
- Differences are largely in degree of detail
- Some variation wrt medication options
- Some variation in staging tools
- User friendliness, or lack of
Current Treatment Options for Obesity

Potency includes many factors, such as the amount, rate, and sustainability of weight loss, and the long-term resolution of adiposopathy and fat mass disease. Potency varies greatly for each individual (i.e., long-term adherence to a lifestyle program can be as potent as gastric bypass surgery).

Risk/Cost

Surgery
(In order of lowest risk/cost and potency):
LAGB<VSG<RNY

Very Low Calorie Diet

Lifestyle + Medication
Includes lifestyle, and anti-obesity medications

Lifestyle
Includes nutrition, physical activity, and behavioral programs

*Potency includes many factors, such as the amount, rate, and sustainability of weight loss, and the long-term resolution of adiposopathy and fat mass disease. Potency varies greatly for each individual (i.e., long-term adherence to a lifestyle program can be as potent as gastric bypass surgery).
Treatment Guidelines

AACE/ACE 2015 Guidelines

Overweight/Obesity Treatment Algorithm

STEP 1
EVALUATION FOR COMPLICATIONS AND STAGING

CARDIOMETABOLIC DISEASE

NO COMPICATIONS
BMI 25–26.9, or BMI ≥ 27

BIOMECHANICAL COMPLICATIONS
BMI ≥ 27 WITH COMPLICATIONS
Stage Severity of Complications
LOW MEDIUM HIGH

STEP 2
SELECT:

Therapeutic targets for improvement in complications + Treatment modality + Treatment intensity for weight loss based on staging

Lifestyle Modification:
MD/RD counseling; web/remote program; structured multidisciplinary program

Medical Therapy:
phentermine; orlistat; lorcaserin; phentermine/topiramate ER; naltrexone/bupropion; liraglutide

STEP 3
If therapeutic targets for improvements in complications not met, intensify lifestyle and/or medical and/or surgical treatment modalities for greater weight loss

Surgical Therapy (BMI ≥ 35):
Lap band; gastric sleeve; gastric bypass

Fed up with how her diet is going Charlene takes a more serious aim at her target weight.
DOCTOR! I'VE BEEN IMPALED!

Well maybe you'll feel better if you lose some weight.
Chronic treatment of hypertension as a model

- In 1960s hypertension was felt to be a disease of stress
- We now have 120+ various medication combinations for HTN
- We treat it as a chronic disease
Barriers to the Use of Medication in Treating Obesity

- Perception that obesity is a disorder of willpower
- Professional perception that weight regain after termination of treatment reflects the failure of the medication; that is, medication is expected to cure obesity
- Prior problems with available medications
  - (Fen-Phen, Sibutramine)
- Regulatory rigidity that limits medication to a few weeks – varies by state
- Licensing boards that persecute physicians for alleged misuse of appetite suppressants – varies by state
- Legislative grandstanding
- Inadequate funding for clinical work in obesity

Some key points

• Medications are effective adjuncts
  – Important to manage expectations
  – Awareness of prior problems
    • (Fen-Phen, sibutramine)

• Can choose based on mechanism of action

• Can and should be considered for chronic use
  – As with any chronic disease

• Current medical-legal status can be a minefield
  – Oregon – Washington – Ohio examples
Combine Diet, Medication, and Behavior Modification

Additive effects of behavior and meal replacement therapy with pharmacotherapy for obesity

Wadden, Arch Int Med. 2001;161:218
Diabetes Prevention Program Research Group

Diabetes Prevention

Cumulative Incidence of Diabetes (%)

Year

Placebo
Metformin
Lifestyle

Diabetes Prevention Program Research Group
Medications That Affect Weight

Weight Positive (Gain)
- Corticosteroids
- Antihistamines
  - Cyproheptadine (Periactin®)
- Many Antidepressants
  - MAOIs, TCAs, most SSRIs (esp paroxetine)
- Opioids
- Atypical Antipsychotics
  - risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone
- Most Antiseizure meds
  - (not topiramate or zonisamide)
- Many Diabetes meds
- Beta Blockers

Weight Negative (Lose)
- Metformin
- Nefazodone (Serzone®)
- Bupropion (Wellbutrin®)
- ?Fluoxetine (Prozac®)
- Incretins
  - Exenatide (Byetta®, Bydureon®)
  - Liraglutide (Victoza®, Saxenda®)

Weight Neutral
- Venlafaxine (Effexor®)
- Citalopram (Celexa®)
- Sertraline (Zoloft®)
Diabetic Medications Affect Weight

**Weight Positive (gain)**
- Insulins
- Thiazolidinediones (TZDs)
  - rosiglitazone (Avandia®)
  - pioglitazone (Actos®)
- Sulfonylureas
  - glimepiride (Amaryl®)
  - glipizide (Glucotrol®)
  - glyburide (DiaBeta®, Glynase®, Micronase®)
- Meglitinides
  - nateglinide (Starlix®)
  - repaglinide (Prandin®)

**Weight Negative (lose)**
- Metformin
- GLP-1 analogues
  - liraglutide (Victoza®, Saxenda®)
  - exenatide (Byetta®, Bydureon®)
- DPP-4 Inhibitors
  - sitagliptin (Januvia®)
- Gliflozins
  - SGLT-2 Inhibitors(sodium-glucose cotransporter 2)
    - canagliflozin (Invokana®)
    - dapagliflozin (Farxiga®)
    - empagliflozin (Jardiance®)
Changes in paradigm

• Initially a “nothing we can do” approach to medication related weight gain
• Gradually learned to avoid weight positive medications if possible
• Now choosing medications based on co effects
  – Metformin in diabetes and prediabetes
    • Note: recommended but not approved for prediabetes or PCOS
  – SGLT-2 inhibitors, Liraglutide in diabetes
  – Topiramate, Zonisamide in migraines and seizure disorders
Medications Used to Treat Weight

- Sympathomimetics
  - Phentermine (1959)
  - Phendimetrazine
  - Diethylpropion
- Metformin
  - Off label
- Topiramate
  - Off label
- Gastric Lipase Inhibitor
  - Orlistat (Alli® – OTC, Xenical® –RX)

- “New” Drugs (since 2012)
  - GLP-1 analogues
    - Liraglutide (Saxenda®)
- Combination
  - Phentermine/Topiramate (Qsymia®)
    - Bupropion/Naltrexone (Contrave®)
- Serotonergic (5HT-2cR)
  - Lorcaserin (Belviq®)
Anti Obesity Agents and Mechanism of Action

J Clin Endocrinol Metab, February 2015, 100(2):342–362
A challenging history – Fen-Phen

Phentermine and Fenfluramine
Phen - Fen

N=121 p<0.001

A challenging history – Fen-Phen

• Caused right and left heart valve lesions and pulmonary hypertension
• ? Incidence “23%”
• Fortunately, most regressed once off of the drug combination
• Subsequently linked to Fenfluramine, a 5-HT\textsubscript{2B} receptor agonist

Pharmacology & Therapeutics; 132 (2):146–157, 2011
More challenging history – SCOUT Trial

SCOUT

- Sibutramine Cardiovascular Outcomes trial
- Randomized, double-blind, placebo-controlled trial ~ 10,000 subjects
- Primary endpoint
  - MACE: CV death, non-fatal MI, non-fatal stroke, resuscitated cardiac arrest
- January 2003 – March 2009
More challenging history – SCOUT Trial

SCOUT
MACE - Overall Population

Kaplan-Meier curves for time to first occurrence of MACE

HR = 1.16 (1.03, 1.31)

No. at Risk
Placebo  4898  4776  4623  4482  3467  1730
Sibutramine  4906  4749  4601  4427  3403  1720

James, NEJM, 2010
Anti Obesity Agents and Mechanism of Action

J Clin Endocrinol Metab, February 2015, 100(2):342–362
Sympathomimetics (SMPs)

- Drug class: phenethylamines – includes amphetamine, methamphetamine, phentermine, diethylpropion, epinephrine, dopamine, and many others.
- Phentermine is not “an amphetamine”
  - Does have phenyl ethylamine backbone
- Phentermine FDA approval in 1959 during a U.S. epidemic of amphetamine addiction. Presumption then – all SMPs shared same adverse effects including addiction potential.
- All obesity drugs reapproved in 1970s for “short-term use” only due to continuing concerns of addiction despite the fact that addiction had occurred only with amphetamine.
Phentermine: Effects

- Weight loss
- Maintenance of weight loss
- Diminution or disappearance of cravings
- Changes in eating behaviors
  - Obsessive eating
  - Improved eating control and diet adherence
- Possible elevation of mood (a mild antidepressant)
- Often increased energy
- Possible improvement in ADD and ADHD
Phentermine: Common Misperceptions on Adverse Effects

Addiction
– Addiction potential in clinical setting – nil
– Withdrawal – no amphetamine-like withdrawal

Adverse cardiovascular effects
– Hypertension – no evidence
– Cardiac valvulopathy – no evidence
– Pulmonary hypertension – no evidence
– Arrhythmias – no established relationship
– Cardiovascular disease – no direct evidence but recall SCOUT Trial experience with sibutramine

Rothman AJT 2010, Hendricks Obes 2011
Phentermine: Actual Adverse Effects

**Most Common**
- Dry mouth – weak anticholinergic agent; usually tolerable
- Insomnia – early, usually fades; if not melatonin may help
- Constipation

**Less Common**
- Bruxism
- Palpitations
- Difficulty with urination in males with prostatic hyperplasia
- Headache

**Uncommon**
- Impotence, changes in libido
- Dysphoria
- Irritability

Typical dosage: 15 -37.5 mg daily in single or split doses
Effect of Phentermine/Topiramate ER on Weight Loss in Obese Adults Over 2 Years

SEQUEL Study

Data are shown with least squares mean (95% CI).
Anti Obesity Agents and Mechanism of Action

J Clin Endocrinol Metab, February 2015, 100(2):342–362
Phentermine HCL/Topiramate
Extended Release

Completion of Risk Evaluation and Mitigation Strategy (REMS) program to inform prescribers and female patients about the increased risk of congenital malformations (especially orofacial clefts) in infants exposed to phentermine HCL/topiramate extended release during the first trimester of pregnancy*

Indications and Use

• Drug Enforcement Agency Schedule IV drug
• Phentermine is a shorter-acting sympathomimetic amine approved as monotherapy as a weight-management drug
• Topiramate is a longer-acting neurostabilizer approved as monotherapy for seizure disorders and migraine headache prevention
• Doses = Once daily in the morning with or without food
  • Starting dose = 3.75 mg/23 mg (phentermine/topiramate extended release)
  • After 14-day intervals, and as clinically indicated, escalate doses to:
    • Recommended dose = 7.5 mg/46 mg
    • Titration dose = 11.25 mg/69 mg
    • Top dose = 15 mg/92 mg

*Completion of the FDA-mandated REMS program is optional and not required prior to prescribing phentermine HCL/topiramate extended release. Implementation of a REMS program by clinicians and pharmacies is intended to provide appropriate safety information to females with reproductive potential.

From Obesity Medicine Association Algorithm
–open access

Reference/s: [174] [175] [504]
Lorcaserin: Those Who Lost ≥ 4.5% Total Body Weight by Week 12 Were Week 52 Responders

Studies 009 and 011, MITT

<table>
<thead>
<tr>
<th>MITT Lorcaserin BID</th>
<th>Week 12</th>
<th>Completed Week 12</th>
<th>Completed Week 52</th>
</tr>
</thead>
<tbody>
<tr>
<td>N = 3097</td>
<td>≥4.5% wt loss</td>
<td>1369/3097 (44.2%)</td>
<td>1083/1369 (79.1%)</td>
</tr>
<tr>
<td></td>
<td>&lt;4.5% wt loss</td>
<td>1168/3097 (37.7%)</td>
<td>680/1168 (58.2%)</td>
</tr>
</tbody>
</table>

Slide courtesy Dr. Steve Smith; May 10, 2012 FDA Advisory Committee Meeting
Anti Obesity Agents and Mechanism of Action

J Clin Endocrinol Metab, February 2015, 100(2):342–362
Lorcaserin

Indications and Use

• Serotonin (5-hydroxytryptamine) 2c receptor agonist anti-obesity medication
• Drug Enforcement Agency Schedule IV drug
• **Dose = 10 milligrams (mg) twice per day**

Potential Drug Interactions

• The safety of lorcaserin co-administration with other serotonergic or anti-dopaminergic agents is not yet established, which includes selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, triptans, bupropion, dextromethorphan, St. John’s Wort

Pharmacokinetics

• Lorcaserin is metabolized in the liver with metabolites excreted in the urine

Reference/s:[172] [173] [503]
Mean Weight Loss
Naltrexone/ Bupropion
COR-I Phase 3
56 Weeks – Completer Population
Anti Obesity Agents and Mechanism of Action

J Clin Endocrinol Metab, February 2015, 100(2):342–362
Indications and Use

- Naltrexone is an opioid antagonist
- Bupropion is an aminoketone antidepressant
- Drug Enforcement Agency Schedule: Not a scheduled drug
- Tablets = 8 mg/90 mg (naltrexone HCL/bupropion HCL extended release)
- Dosing:
  - Week 1 = 1 tablet in AM, no tablets in PM
  - Week 2 = 1 tablet in AM, 1 tablet in PM
  - Week 3 = 2 tablets in AM, 1 tablet in PM
  - Week 4 and beyond = 2 tablets in AM, 2 tablets in PM
Effects of **Liraglutide** and Orlistat on Body Weight in Nondiabetic Obese Adults

Data are mean (95% CI) for the ITT population

Liraglutide Weight Loss: Two Years

Liraglutide 3.0 mg for 1 year (and then maintained on 2.4/3.0 mg for the second year) maintained a mean weight loss of 10.3±7.1 kg from screening over 2 years.

Anti Obesity Agents and Mechanism of Action

J Clin Endocrinol Metab, February 2015, 100(2):342–362
Liraglutide

Indications and Use

• Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist
• Drug Enforcement Agency Schedule: Not a scheduled drug
• Solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg
• Inject subcutaneously in the abdomen, thigh, or upper arm; the injection site and timing can be changed without dose adjustment
• Recommended dose of liraglutide for treatment of obesity is 3 mg daily, any time of day, without regard to the timing of meals
• Dosing:
  − Week 1 = 0.6 mg per day
  − Week 2 = 1.2 mg per day
  − Week 3 = 1.8 mg per day
  − Week 4 and beyond = 3.0 mg per day

*Completion of the FDA mandated REMS program is optional and not required prior to prescribing liraglutide. Implementation of the REMS program by clinicians and pharmacies is intended to provide appropriate safety information pertaining to the potential serious risks of taking liraglutide, which include medullary thyroid carcinoma (MTC) and acute pancreatitis.

Reference/s: [506]
Other rational combinations?

• All are approved in some usages, but not approved as combinations
• Lorcaserin-Phentermine
• Pramlintide-Phentermine
• SGLT inhibitor combinations
Other indications?

- Is it reasonable to start or continue use after bariatric surgery? (regain)
### Drugs approved for ‘long term’ treatment

#### AACE/ACE

---

#### WEIGHT-LOSS MEDICATIONS APPROVED BY THE FDA FOR LONG-TERM TREATMENT OF OBESITY

<table>
<thead>
<tr>
<th>Anti-obesity Medication (Trade Name)</th>
<th>Mechanism of Action, Study Name, Study Duration (% TBWL)</th>
<th>Dose</th>
<th>Common Side Effects</th>
<th>Contraindications, Cautions, and Safety Concerns</th>
<th>Monitoring and Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orlistat (Xenical®) (All®) - CIT 1969</td>
<td>Lipase inhibitor XENOSO: 1 yr 4.6% 4 yr 2.6%</td>
<td>120mg PO TID before main meals 60mg PO TID before main meal</td>
<td>- Steatorrhea - Fecal urgency - Abdominal pain - Headache</td>
<td>Pregnancy and breastfeeding - Chronic malabsorption syndrome - Cholestasis - Gastrointestinal discomfort - Rare severe liver injury - Cholecystitis - Malabsorption of fat-soluble vitamins - Effects on other medications - Tachyphylaxis (enhance) - Antiepileptics (decrease) - Levetiracetam (decrease)</td>
<td>Monitor for: - Cholelithiasis - Hepatitis</td>
</tr>
<tr>
<td>Lorcaner (Belviq®) 2012</td>
<td>Serotonin CHT2 receptor agonist BLOSSOM RQ/DOM 1 yr 10.1%–3.6% 2 yr 3.7%</td>
<td>10mg PO QD</td>
<td>- Headache - Nausea - Abnormal vision - Fatigue - Xerostomia - Dry eye - Constipation - Blurred vision - Back pain - Nausea/vomiting - Hyperlipidemia</td>
<td>Pregnancy and breastfeeding - Somnolence syndrome or neurologic manifestations - Safety &amp; efficacy in patients with liver disease - Concurrent use of SSRIs, SNRIs, MAOIs, bupropion, St. John’s wort may increase risk of developing serotonin syndrome - Uncontrolled mood disorder - Cognitive impairment - Avoid in patients with severe liver injury or eGFR &lt; 60</td>
<td>Monitor for: - Symptoms of cardiac valve disease - Bistriolinsa - Somnolence syndrome - Neuraxial malignant syndrome - Depression - Severe mood alterations, euphoria, dissociative state - Drowsiness</td>
</tr>
<tr>
<td>Phenetermine/Topiramate ER (Qsymia®) 2012</td>
<td>Noreleasing agent (phenetermine) GABA receptor modulator (topiramate) FEWP CONQUEER 6GUEL 1 yr 8.8%–9.0% 2 yr 8.4% on high dose &amp; 4.4% on treatment dose 2 yr 8.7% on high dose &amp; 7.5% on treatment dose</td>
<td>Starting doses: 3/15 mg PO QD for 2 weeks, recommended dose: 7.5/45 mg PO QD</td>
<td>- Headache - Paresthesia - Insomnia - Decreased appetite - Nausea - Constipation</td>
<td>Pregnancy and breastfeeding - Hypothyroidism - Hyperuricemia - Asthenia - Angioedema - Constrictive pericarditis - Amnesia - Cognitive impairment (concentration and memory)</td>
<td>Monitor for: - Increased heart rate - Depression, somnolence or worsening depression especially on maximum dose - Hypokalemia (be especially with HCTZ or furosemide) - Atelectasis and/or ocular pain - Acute kidney stone formation - Hypoglycemia in patients taking DPP4 treated with insulin and/or sulfonylureas - Potential for lactic acidosis (hypoketemic, normocoric hyperlactatemia) in combination with metformin - MADD: (allow ≥ 14 days between discontinuation) 15 mg/92 mg dose should not be discontinued abruptly (≥4 weeks) or stopped immediately - Health care professional should check BUN/Glu before initiating, followed by monthly, self testing at home - Monitor electrolyte/creatinine changes before and during treatment: Can cause mental/motor impairment in women taking birth-control pill/oral contraceptives alter metabolism of oral agents and xenobiotics</td>
</tr>
</tbody>
</table>
## Drugs approved for ‘long term” treatment AACE/ACE 2/2

<table>
<thead>
<tr>
<th>Anti-obesity Medication (Trade Name)</th>
<th>Mechanism of Action, Study Name, Study Duration: %TBWL Greater Than Placebo</th>
<th>Dose</th>
<th>Common Side Effects</th>
<th>Contraindications, Cautions, and Safety Concerns</th>
<th>Monitoring and Comments</th>
</tr>
</thead>
</table>
| Naltrexone ER/ Bupropion ER (Contevo®) 2014 | Opiate antagonists (Naltrexone) Resist inhibitor of DA and NE (Bupropion) | Titrate dose:  
- Week 1: 1 tab (89 mg) PO QD  
- Week 2: 1 tab (89 mg) PO ID  
- Week 3: 2 tabs (total 168 mg) PO QAM and 1 tab (89 mg) PO QHS  
- Week 4: 2 tabs (total 168 mg) PO QD | - Nausea  
- Headache  
- Insomnia  
- Vomiting  
- Constipation  
- Diarrhea  
- Dizziness  
- Anxiety  
- Haronoma |  
- Pregnancy and breastfeeding  
- Uncontrolled hypertension  
- Seizure disorder  
- Arterial aneurysm  
- Ballooning fenestration  
- Severe depressions  
- Drug-related withdrawal  
- (Concomitant MAOIs within 14 days)  
- Chronic pleurisy  
- Cardiac arrhythmia  
- Dose adjustment for liver and kidney impairment  
- Neuroglycopenia  
- Uncontrolled hypertension  
- Generalized anxiety disorder  
- Bipolar disorder  
- Safety data lacking in patients who have depression  
- Seizures (Bupropion lowers seizure threshold) | Monitor for:  
- Irregular heart rate and blood pressure  
- Hypersomnia depression and suicidal ideation  
- Worsening of manic episodes  
- Loin pain (nabroreo)  
- Hypoglycemia in patients having T2DM treated with insulin and/or sulfonylureas  
- Seizures (Bupropion lowers seizure threshold)  
- MAO (allow 14 days between discontinuation)  
- Decrease in appetite for patients with renal and hepatic impairment  
- Avoid taking medication with high-dose oral  
- Causing false positive, positive test for amphetamine  
- Bupropion inhibits CYP2D6 |
| Liraglutide 3 mg (Saxenda®) 2014 | GIP-1 analog SCALE Obesity & Prediabetes 1 yr: 50% | Titrate dose weekly by 0.6 mg as tolerated by patient (side effects)  
- 16.5 mg SC QD  
- 2.4 mg SC QD  
- 2.8 mg SC QD  
- 4.2 mg SC QD  
- 5.4 mg SC QD | - Nausea  
- Vomiting  
- Diarrhea  
- Constipation  
- Headache  
- Depression  
- Insomnia at bedtime |  
- Pregnancy and breastfeeding  
- Personal or family history of medullary thyroid cancer or MEN2  
- Pancreatitis  
- Acute gallbladder disease  
- Gastritis  
- Severe renal impairment can result from vomiting and dehydration  
- Use caution in patients with history of pancreatitis  
- Use caution in patients with cholelithiasis  
- Suicidal ideation and behavior  
- Injection site reactions | Monitor for:  
- Pancreatitis  
- Cholelithiasis and Cholecystitis  
- Hypoglycemia in patients having T2DM treated with insulin and/or sulfonylureas  
- Increased heart rate  
- Discontinuation from nausea/vomiting  
- Injection site reactions |  

Abbreviations: BID = twice daily; DA = dopamine; FDA = US Food and Drug Administration; GI = gastrointestinal; HOMA RO = homeostasis model of insulin resistance; NE = noradrenaline; SC = subcutaneous; T2D = type 2 diabetes mellitus; TBWL = % total body weight lost

FDA indication for all medications: BMI > 30 kg/m² or BMI 27–29.9 kg/m² with significant comorbidity.

After 3 to 4 months of treatment with aminoglucoside medication:

- For naltrexone ER/Bupropion ER and derivatives:
  - If the patient has lost at least 5% of their baseline body weight at 12 weeks on the maintenance dose, the medication should be discontinued.
  - For phentermine/topiramate ER:
    - Continue medication if the patient has lost >5% body weight after 12 weeks on the recommended dose (11 mg/42 mg). If the patient has not lost at least 3% of body weight after 4 weeks on the recommended dose for 12 weeks then the medication should be discontinued. The patient can be maintained on a maximum dose of (11 mg/92 mg). If patient has not lost at least 5% body weight after 12 additional weeks on the maximum dose, the medication should be discontinued.

References:
Summary

• Use of Anti Obesity Medications is a valuable adjunct to other treatment modalities
• It is important to understand barriers to use of medications
• Learning correct usage takes time but resources are available
• Managing expectations is important – even small amounts of weight loss have large effects
Thank You!

Rick Lindquist M.D.
richard@richardlindquistconsulting.com
Cell 206.465.6905
Obesity in 2016 (from WHO)

- Worldwide obesity has more than doubled since 1980.
- Undernutrition and obesity can exist together—“double burden”
- 39% overweight and 14% obese
Objectives

• Become familiar with the most common surgical procedures for weight loss

• Awareness of endoscopic treatments for obesity
4 Most Common Weight Loss Surgery Procedures in the United States

Adjustable Gastric Band (Lap Band)
- Stomach pouch
- Adjustable band
- Port placed under skin

Roux-en-Y Gastric Bypass (RYGB)
- Bypassed portion of stomach
- Food
- Digestive juice
- Gastric pouch
- Jejunum

Duodenal Switch (DS)
- Gastric sleeve (new stomach)
- Partially Resected Stomach
- Duodenal Switch
- Digestive loop
- Bilio-Pancreatic loop
- Common loop
- Removed portion of stomach

Vertical Sleeve Gastrectomy (Gastric Sleeve)
- Gastric sleeve (new stomach)
- Removed portion of stomach

www.bariatric-surgery-source.com
Key Surgical Points

• Most procedures are done laparoscopically, OR time ranges 45 min- 3 hours on average

• Very safe, minimal blood loss

• <0.2% mortality

• 0-2 night hospital stays
Key Surgical Points

• Early ambulation (within 4 hours postop)
  – can shower
  – use of IS and CPAP immediately postop

• Hydrate
  – Goal 64 oz calorie-free liquids

• Start MVI and other vitamins when able to tolerate (1-3 wks)
Laparoscopic Adjustable Gastric Band

- Less utilized now
- Band concerns
  - Slip
  - Erosion
- Port site concerns
  - Access only with a huber needle
Laparoscopic Sleeve Gastrectomy

- Most commonly performed now

- Types of complications
  - Leak
  - Bleeding
  - Obstruction/stenosis
  - GERD
Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)

- Longest history/evolution

- Types of complications
  - Leak
  - Bleeding
  - SBO/Internal hernia
  - Marginal ulcers

- Malabsorption component
Laparoscopic Duodenal Switch (DS)

- Starting to increase in numbers
- Most malabsorptive
- Vitamin compliance/Dietary compliance
BMI 50-60, 30 pts duodenal switch vs 30pt LRYGB

- **DS** greater weight loss and greater improvements in low-density lipoprotein cholesterol, triglyceride, and glucose levels 5 years
- Improvements in health-related quality of life were similar
- Duodenal switch was associated with more surgical, nutritional, and gastrointestinal adverse effects.
Key Diet Education

- 45-60 grams of protein daily
- Start with slow drinks/bites all day, but progress to 3 meals
  - Over 2-3 months
- Exercising immediately- low impact, light weights (1-5lbs)
- MVI for everyone
- Other vitamins
  - B12 and/or B-complex
  - Vitamin D3
  - Calcium citrate
  - ADEK- DS only
Endoscopic treatments

**Intragastric Balloons**
- Double balloon and single balloon available (Orbera, ReShape, Allurion)
- Space occupying
- Nausea
- 3-6 month duration
- FDA approval BMI 30-40
Endoscopic treatments

*Intragastric Balloons*
- Double balloon and single balloon available
- Space occupying
- Nausea
- 3-6 month duration
- FDA approval BMI 30-40
Endoscopic treatments

Endoscopic gastric plication
- Suturing done with the endoscope
- 3-4 hour procedure
- Requires GETA
- DDW 242 patient, 19.8% TBW at 18 months
Additional Treatments

• AspireAssist - FDA approved
  – 111 pts, 37.2% EBW

• GI Windows
  • Magnets - jejunoileal anastomosis
  • Placed in GI lab
  • Czech 10pts, 28.3% EBW
  • HgA1c improved

• Revita
  • Duodenal mucosal resurfacing
  • Hot balloon
  • Type 2 DM - 1.2%
Questions?
Late complications (>30 days)

• Marginal Ulcers - Gastric Bypass and Duodenal Switch
  – PPI +/- H2 blocker
  – Carafate slurry qid
  – EGD

• Stricture - Gastric Bypass and Duodenal Switch
  – EGD with dilation +/- kenalog injection, BIOPSY
  – Hypertrophic scar vs ischemic
Health Equity and Obesity Disparities: Social Causes and Consequences

Ginny Garcia, PhD
Dept. of Sociology, PSU
gin5@pdx.edu
Oct. 21, 2016
Social Determinants of Health

- **Social Determinants of Health**: the economic and social conditions that influence individual and group differences in health status.
- “Social determinants of health reflect the social factors and physical conditions of the environment in which people are born, live, learn, play, work, and age. Also known as social and physical determinants of health, they impact a wide range of health, functioning, and quality-of-life outcomes.” (Healthy People 2020)
  
Health Disparities

- **Health Disparities**: “a particular type of health difference that is closely linked with social, economic, and/or environmental disadvantage.”
  - Avoidable gaps between subgroups
- Persistent disparities in numerous health outcomes are observed on the basis of:
  - Race/ethnicity
  - Sex/Gender
  - Disability Status
  - Age
  - Socioeconomic Status/Position

Sources: Healthy People 2020 (https://www.healthypeople.gov/2020/about/foundation-health-measures/Disparities)
CDC. MMWR 2013; 62(Suppl 3).
Disparities in Obesity

• No groups have been immune to increasing levels of obesity

• Who is disproportionally affected?
  – Generally > Women, Black and Hispanic, those with lower incomes and education
  – Various social positions interact to produce a more complicated picture:
    • The most socially disadvantaged (low-educ/income Black women) have highest rates of BMI growth, while most socially advantaged have lowest rates (high educ/income White men) (Ailshire & House. Social Forces 2011. 90(2): 397-423)
Obesity in the U.S.

- Obesity is an immensely complex issue
- Intense debate surrounds the extent to which various factors have led to such increases in obesity
- Factors include:
  - Major shifts in lifestyle patterns (sedentary, meals away from home, snacking); Western diet
  - Abundant use of additives in food supply
  - Overabundance of food
  - Lack of access to healthy options
  - Lack of information or misleading information
Social Determinants of Obesity

• Lack of available resources, e.g. affordability of healthy options
• Neighborhood disorder: safety, access to space
• Socio-cultural factors: social support, health behaviors and attitudes
• Concentrated disadvantage: poverty, segregation
• Political Factors: food policy (subsidies), lack of regulation of food industry
The Food Environment

• Recognize the influence of the food environment
  – *Toxic/Obesogenic Food Environment*: the sum of influences that the surroundings, opportunities, or conditions of life have on promoting obesity in individuals and populations
  – What we are seeing is a normal response to an abnormal environment (Egger & Swinburn. *BMJ* 1997; 315(7106): 477-480)
  – An ecological approach reduces emphasis on obesity as an individual problem (Story et al. *Annu. Rev. Public Health* 2008. 29:253–72)
The Food Environment

• **Food Desert**: a term used to describe areas that have poorer access to healthy choices
  – Less grocery store availability and more fast food in urban areas
  – Obesity in disadvantaged groups is influenced by access to supermarkets and safety of neighborhoods (Lovasi et al. *Epidemiol Rev* 2009. 31:7-20)

• Common approach to obesity takes a downstream approach, i.e. focus on and modify behavior/diet instead of the food environment
Social Consequences

• A prevalent message is that obesity is mainly an issue of personal choice (or a lack of will power)
  – But, keep in mind that obesity has increased despite increased knowledge, awareness, and education about nutrition and exercise

• People with obesity suffer from bias and discrimination in multiple settings

Weight Bias and Stigma

• Stigma (a representation of society’s negative perceptions)
  – Weight bias leads to: lower wages over life course, hiring prejudice, disparities in educational outcomes, and bullying
  – Health Setting: Patients feel stigmatized and may avoid care
    • Associations with increased rates of depression and anxiety
    • Evidence of less intervention, less time spent

Sources: Sobal, J. *A Soc of Food and Nutrition* 2004; 383-402.
Weight Bias and Stigma

• Media Messages
  – Promotes intense fear of weight gain, overweight, and obesity
  – Stereotypical representations of those with obesity

• No productivity differences observed in those with obesity vs. without
Research Findings

- Better working alliance was associated with increased patient activation, regardless of weight
- Perceived weight bias lowered patient activation
- Patient activation is a promising avenue through which to promote the adoption and maintenance of healthy behaviors

Recommendations

• Recognize the role of external forces and the complexity of the issue
• Examine/consider findings that suggest obesity on its own may not be directly connected to ill-health/mortality (see resources for suggested reading)
• Keep focus on health promotion and adoption of healthy behaviors
• Acknowledge possible biases
Recommendations

• Issues of best practice
  – Offer support with weight management
  – Promote healthy eating and active lifestyles/wellness to all patients
  – Increase accessibility if possible (comfortable chairs, etc.)
  – Provide access to resources for patients that increase their knowledge/agency (improve working alliance and patient activation) – empower your patients
  – Use appropriate language: “People with obesity”
  – Help with development of wellness policies

• Administer surveys to assess your practice: http://biastoolkit.uconnruddcenter.org/toolkit/Module-8/8-05-SurveyWeightSensitive.pdf
Survey Excerpt (Bias Toolkit)


Below is a series of questions that ask you about the health care services that you receive, specific to your weight. Thinking about the place that you go to for your regular health care (your medical group), how do you rate the items listed below? Please rate the quality of care you receive for each of the following items, by circling one number for each question.

1. Does your provider address concerns about your weight appropriately?
   - Always
   - Most of the time
   - About half of the time
   - Sometimes
   - Rarely/Never

2. Does your provider ask your permission before discussing your weight with you?
   - Always
   - Most of the time
   - About half of the time
   - Sometimes
   - Rarely/Never

3. Does your provider use sensitivity when discussing your weight to make you feel at ease?
   - Always
   - Most of the time
   - About half of the time
   - Sometimes
   - Rarely/Never

4. Does your provider offer useful information to you about healthy eating and weight loss?
   - Always
   - Most of the time
   - About half of the time
   - Sometimes
   - Rarely/Never
Resources

• Toolkit for Healthcare Providers
  – UCONN Rudd Policy Center makes available a comprehensive toolkit for providers that includes:
    • Ways to improve patient-provider interactions
      – Example scripts for discussing weight
    • Recommended changes to office environments
    • Resources for Patients – how to empower

• Available at: http://biastoolkit.uconnruddcenter.org/
Resources

• Implicit Association Test (IAT):
  – https://implicit.harvard.edu/implicit/education.html

• Harvard Center for Public Health > Webcast: Why We Overeat: The Toxic Food Environment and Obesity
  – https://theforum.sph.harvard.edu/events/why-we-overeat/

• Suggested Readings:
Addressing Food Insecurity in Health Care

Health Care Partnerships Program
Oregon Food Bank
Summer 2016
Social Determinants of Health

Narrow Focus = Deficient Results

Source: Oregon Health Authority
CDC says 86% of Health Care costs due to diet-related chronic disease.

71% of Medicaid population is food insecure (2014 MBRFS).

72% learn about new resource with post screening assistance (according to preliminary evaluations).
FOOD INSECURITY IN OREGON

• Food insecurity has grown in OR more than all states except Louisiana and Mississippi
• 51% of kids qualify for free/Reduced lunch
• Oregon has one of the greatest problems of income inequality; between rich and poor and between whites and people of color
• Lower than average wages and higher than average housing costs
• Job growth primarily in low wage jobs
• Un/underemployment still up to 30% for certain for populations of color
Motivated System - Metrics
Try Nutrition First!

High correlation between food insecurity, which = poor diet and:

• Poor child physical & mental development
• Depression & ADHD in all ages
• Cancer, Hypertension, High Blood Pressure, Obesity, and Diabetes
• Poor academic performance & childhood behavior problems
• Problems in pregnancy with smaller, sicker babies
• Seniors who are food insecure have a decreased capacity to maintain independence.
First Thing’s First

• Assess your population
• Targeting special assistance and interventions, depending on setting, 30-65% screening positive
• Positives most motivated to act, 78% screened and assisted with resources find something new
• 60% of over 60 not even on SNAP
• Drive people to existing resources before developing new ones, efficient use of limited resources, avoid duplication and learn about gaps and weaknesses in existing resources
• Clinicians need food insecurity info for accurate diagnosis & treatment
Simple Screening & Intervention
Quickly Spreading in Oregon

TOOLS: 1 page overview, 2 validated questions, 1 page EHR ready local resource handout in many languages, ICD codes, EHR support

MODEL: On-going written screening integrated into clinic flow
Results to clinician for exam
Resource handout in AVS
Immediate review with patient by staff, intern, or volunteer

FOLLOW-UP: phone check-in a week later, provider check-in at next visit, review handout for other possible actions
For each statement, please tell me whether the statement was “often true, sometimes true, or never true” for your household:

(Any patient answering with a 1 or 2 response is considered food insecure)

A. Within the past 12 months we worried whether our food would run out before we got money to buy more.  1. often true  2. sometimes true  3. never true  4. don’t know or refused

B. Within the past 12 months the food we bought just didn’t last and we didn’t have money to get more.  1. often true  2. sometimes true  3. never true  4. don’t know or refused
NOT ENOUGH FOOD FOR YOUR FAMILY?
NEED HELP COOKING/SHOPPING FOR
HEALTHY FOOD ON A BUDGET?

You might qualify for SNAP (Supplemental nutritional Assistance Program, formerly known as Food Stamps)
• Go to http://www.oregon.gov/dhs/assistance/pages/foodstamps/foodstamps.aspx or call 211*

If you are pregnant or have children under five, you may qualify for WIC (The Special Supplemental Nutrition Program for Women, Infants, and Children)
• Go to http://jacksoncountyor.org/hhs/Public-Health/Women-Infants-and-Children
• Or call 541-774-8203 and schedule an appointment

If you are a senior 60+, you may qualify for a senior food program: Call Peggy at 541-774-4309

Most farmer’s markets accept SNAP & WIC, several will add to SNAP dollars so you can buy more!
• http://rvgrowersmarkets.com/ (find market near you that takes SNAP/WIC/Senior Direct

There may be a food pantry in your neighborhood where you can get a box of food for free!
• Go to http://www.accesshelps.org/Page.asp?NavID=420 or call 541-774-4336

Summer meals for kids Go to http://www.summerfoodoregon.org/ or call 211*

Volunteer, learn how to garden and take some produce home with you!
• ACCESS Food Share Gardens, 541-779-6691 ext. 309

Learn to cook healthy food and shop on a budget: Call Robin 541-690-3989 & visit https://www.foodhero.org/
1. Stand Alone: Add questions in writing to check-in process or give to patients in exam room. Then, provide food insecure patients with resource handout and have someone review it with them and connect to new resources.

2. Integrated: Questions added to comprehensive health assessment with resource information & supported follow-up for the food insecure.
Current Status

• About 280 clinics & hospitals screening, plus Head Start & WIC
• Urban & Rural Success
• Now an Oregon Performance Improvement Metric,
  model screening process developed by CCO TAG
What More Can A Clinic or Hospital Do?

• Cooking & smart shopping classes
• Gardening classes & assistance
• Diabetes clinic/pantry partnerships
• On-site produce distributions
• Veggie Rx programs
• Convening of human services & health care communities to address social determinants of health
Possible New Funders for Food Assistance and Nutrition Education Initiatives

• Local Hospital Community Benefit Funds
  • CCO Incentive Fund Grants
  • Grants from Health Insurers, Kaiser, Anthem, Blue, Providence, Pacific Source...

• Medical Equipment Companies
• Electronic Health Record Providers
• Condition specific Medicaid billing (flex funds)
Contact

Lynn Knox
Statewide Health Care Liaison
Oregon Food Bank
503-853-8732
lknox@oregonfoodbank.org
Healthy Weight Management in Primary Care: Considering the Whole Person

Helen Bellanca, MD, MPH
October 2016
I have no financial relationships to disclose
The idea that overweight and obesity are due to solely to calorie imbalance is a gross oversimplification.

Viruses
Gut microbiome
Resistance to leptin
Artificial sweeteners and food additives
Genetic programming
Chronic stress
WHERE DOES STRESS FACTOR INTO OBESITY?

- **Pregnancy**: Epigenetics
- **Early childhood**: Adverse childhood events
- **Adolescence**: Discrimination due to weight, culture of thinness
- **Adulthood**: Poverty, racism, futility of weight loss programs, sleep deprivation
Epigenetics are heritable changes to gene function.

Severe stress from previous generations affects your risk of obesity.³

Some populations (Native Americans, African Americans, refugees, war and famine survivors) have persistent, intractable obesity driven by survival instincts that are embedded in their genes.

ACEs Study

- 1995-1997 Kaiser/CDC study in California
- 17,000 participants, all HMO members
  - 75% white
  - 66% over age 50
  - 39% college graduates
  - All employed
- Asked about childhood experiences and current health status

https://www.cdc.gov/violenceprevention/acestudy

Adverse childhood Experiences (ACEs)

Three categories

Abuse
- physical abuse
- emotional abuse
- sexual abuse

Neglect
- physical neglect
- emotional neglect

Household Dysfunction
- mental illness
- substance use disorder
- incarceration
- domestic violence
- parent abandonment
Adverse childhood Experiences (ACEs)

Three categories

Abuse
- physical abuse (28%)
- emotional abuse (21%)
- sexual abuse (11%)

Neglect
- physical neglect (10%)
- emotional neglect (15%)

Household Dysfunction
- mental illness (19%)
- substance use disorder (27%)
- incarceration (5%)
- domestic violence (13%)
- parent abandonment (23%)
Prevalence of ACEs

- 0 ACEs: 36%
- 1 ACE: 26%
- 2 ACEs: 16%
- 3 ACEs: 10%
- 4+ ACEs: 12%
The ACE Score and the Prevalence of Severe Obesity (BMI ≥35)

Percent obese (%)

ACE Score

0 1 2 3 >=4

Anda, ACE interface 2013
Childhood Abuse and obesity

Adults with a history of physical, emotional or sexual abuse were 34% more likely to be obese than adults without that history\(^1\)

Among adults undergoing gastric bypass surgery, 69% reported childhood abuse\(^2\)

Additional sources of STRESS

- Poverty
- Racism
- Violence in the community
- Discrimination based on weight
- Futile cycle of weight loss and gain
How does stress cause weight gain?

Cortisol levels ➞ Blood sugar + Insulin resistance + Reward from eating + Thyroid hormone conversion ➞ Mood, sleep and cognitive ability ➞ Weight gain, visceral fat deposition
Why would obesity be a physiological response to severe, persistent stress?

Doesn’t excess weight cause more health problems?
Surprising **benefits** of overweight and obesity

<table>
<thead>
<tr>
<th>Disease</th>
<th>Overweight and obese people have:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary heart disease</td>
<td>Lower mortality in hospital and at one year, fewer complications</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Lower mortality and lower amputation risk</td>
</tr>
<tr>
<td>Stroke</td>
<td>Better survival rates</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>Decreasing mortality with increasing BMI</td>
</tr>
<tr>
<td>COPD</td>
<td>Improved prognosis from acute exacerbation</td>
</tr>
<tr>
<td>Stroke</td>
<td>Better survival</td>
</tr>
<tr>
<td>Non-bariatric general surgery</td>
<td>Lower mortality</td>
</tr>
</tbody>
</table>

Mortality Data

JAMA meta-analysis of all-cause mortality by weight category published 2013

• Lowest mortality in overweight people (BMI 25-30)

• Equal mortality rates for normal weight (18-25) and Grade 1 obesity (30-35)

• Mortality only increased for Grade 2 obesity (BMI >35) and higher

Message #2

Excess weight is not the problem.
Excess weight is the response to the problem.
Old paradigm: Poor Health Behavior Causes Obesity Which Causes Disease

- Poor eating, sedentary behavior, stress
- Overweight and obesity
- diabetes
- cardio-vascular disease
- cancer
- Early death
New paradigm: Poor Health Behavior Causes Disease and Obesity

Poor eating, sedentary behavior, stress

Inflammation, hormone disruption

Overweight and obesity

Protective effect on mortality

- diabetes
- cardiovascular disease
- cancer
Obesity May Not Be the Problem
It May Be the Solution

• Obesity may be a self-protective mechanism to mitigate high-stress environment
  – low quality diet
  – lack of sufficient sleep
  – toxins/viruses in the environment
  – trauma, abuse, violence, oppression, poverty

• Metabolic disturbances lead to disease and poor outcomes

• Excess weight is creating resilience
It’s not the weight that is the problem

- Unhealthy, overweight
- Unhealthy, thin
- Healthy, overweight

People with unhealthy behaviors

People with excess weight
BIAS

• Our culture has a very strong anti-overweight bias
  – Schools
  – Employment
  – Media

• Health care providers are not immune from this bias, and we can hide behind a health argument
Change your practice

- Guard against attribution bias
  - Not all symptoms are related to weight

- Stop weighing people routinely
  - Exceptions: pregnancy, children, preop, medication dosing
  - If you must weigh: Ask permission, weigh at end of visit, keep results private (including from patient)

- Stop counseling people to lose weight
  - Instead, ask everyone about health behaviors, and counsel on improvement of those behaviors. Weight loss may happen incidentally but it is not the goal.
First, do no harm

• The stress of being overweight and attempting to lose weight is worse for one’s health than the weight itself

• Health care providers contribute to this discriminatory, shaming culture by weighing people routinely and endorsing a narrative that blames the patient for their weight and attributes all problems to excess weight

• People **routinely** avoid needed health care because they do not want to be weighed

• We should stop focusing on the weight and instead focus on promoting healthy behaviors with EVERYONE
WEIGHT STIGMA in Health Care

False assumptions

• Obese individuals are entirely responsible for their weight
• All overweight individuals eat unhealthy food and eat too much
• All overweight individuals are lazy and sedentary
• Stigmatizing overweight patients may help because it will motivate them to make necessary behavior changes
• Diet and exercise can result in permanent weight loss if you stick with it
Behavior Change recommendations For Every Patient

• Ask everyone about behaviors (don’t assume)

• Counsel to modify behaviors that are unhealthy
  – Insufficient sleep (need 7-9 hours a night)
  – Excessive stress, poor coping (exercise, mindfulness)
  – Insufficient activity (30-60 minutes of moderate activity every day)
  – Poor nutrition (watch beverages, increase fiber, vegetables, legumes, whole grains, limit meat, dairy, and processed foods)

• Measure behavior changes instead of weight to track progress
Health At Any Size

Regardless of weight or BMI, you can mitigate metabolic disturbances that lead to disease through exercise, sleep, stress reduction, and healthy eating.
Healthy Weight Management

**Weight loss**
- Short-term
- Focused on getting to a certain number
- Success defined by pounds lost
- The more pounds you lose, the better
- Aim to get to a “normal” weight
- Weight-specific reward and punishment
- People who are overweight work to lose weight

**Healthy Weight Management**
- Lifelong
- Focused on health
- Success defined by reaching behavior goals
- Halting weight gain is a successful outcome
- Fit and healthy at any size
- Weight-neutral self-care
- Everyone works to adopt healthy habits
Thank you!

Helen Bellanca, MD, MPH

helen@healthshareoregon.org

503-416-4983
Developing Culturally Competent Health Communication Strategies

Asani H. Seawell, Ph.D.
Psychology Resident, Legacy Health
Associate Professor of Clinical Psychology, Pacific University
October 21, 2016
One Size Does Not Fit All
The importance of culturally competent communication: Three reasons

• Keep in mind that conservative estimates are that 50% of medical advice goes unheeded
• The majority (60 to 80 percent) of medical diagnoses and treatment decisions are made from the medical consultation processes
• Discrepancy in views of communication
What is cultural competence in healthcare?

• The goal of culturally competent health care services is to provide the highest quality of care to every patient, regardless of race, ethnicity, cultural background, English proficiency or literacy.

• The ability of providers and organizations to understand and integrate these factors into the delivery and structure of the health care system.
The ADRESSING model

Age
Disability
Religion
Ethnicity
Social & Economical Class
Sexual Orientation
Indigenous Background
National Origin
Gender
Culturally Competent Communication in the Delivery of Healthcare Services

• “...does **not** imply knowing everything about all cultures we are engaged with...it does, however, require **demonstration of respect** for differences, eagerness to learn about other cultures, acceptance of different epistemologies, and a **flexibility** and willingness to **adjust**, change and reorient where required” (Le Roux, 2002)
Cultural Competence & Communication: What we bring to the table

• Communication strategies that we employ that focus only on facts are limited
• Basic attitudes that have the potential to help the clinical relationship: Curiosity, empathy, respect, and humility
• An approach that focuses on inquiry, reflection, and analysis throughout the care process is most useful for acknowledging that culture is just one of many factors that influence an individual's health beliefs and practices.
Cultural Competence & Communication: What we bring to the table

- Awareness of the influences of sociocultural factors
- Acceptance of the physician's responsibility to understand the cultural aspects of health and illness
- Recognition of personal biases
- Respect and tolerance for cultural differences
- Acceptance of the responsibility to combat racism, classism, ageism, sexism, homophobia, and other kinds of biases and discrimination that occur in health care settings
Strategies for culturally competent communication

- Provide interpreter services
- Recruit and retain minority staff
- Provide training to increase cultural awareness, knowledge, and skills
- Coordinate with traditional healers
- Use community health workers
Strategies for culturally competent communication

• Incorporate culture-specific attitudes and values into health promotion tools
• Include family and community members in health care decision making
• Expand hours of operation
• Provide linguistic competency that extends beyond the clinical encounter to the appointment desk, advice lines, medical billing, and other written materials
The Process ASK Questions...

- **Awareness:** Am I aware of my biases and prejudices towards other cultural groups, as well as racism and other "isms" in healthcare?
- **Skill:** Do I have the skill of conducting a cultural assessment in a sensitive manner?
- **Knowledge:** Am I knowledgeable about the worldviews of different cultural and ethnic groups?
- **Encounters:** Do I seek out face-to-face and other types of interactions with individuals who are different from myself?
- **Desire:** Do I really "want to" become culturally competent?
Cultural Competence & Communication: Key Points to Take Home

- There is a growing movement to make health services more culturally competent and to assure that global health work is culturally informed.
- Cultural competency has been defined in many different ways, and it has provoked considerable controversy over its assumptions, effects, and necessity.
- Cultural competency models have varied considerably, ranging simply awareness to more dynamic ways of interacting with patients.
- More than knowing exactly how to perform, it is more important to ask the right questions.